ישראל - עברית - Ministry of Health

gilead sciences israel ltd - sofosbuvir; velpatasvir; voxilaprevir - טבליות מצופות פילם - voxilaprevir 100 mg; velpatasvir 100 mg; sofosbuvir 400 mg - sofosbuvir, velpatasvir and voxilaprevir

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - sofosbuvir; velpatasvir - טבליות מצופות פילם - velpatasvir 100 mg; sofosbuvir 400 mg - sofosbuvir

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - sofosbuvir; velpatasvir - טבליות מצופות פילם - velpatasvir 100 mg; sofosbuvir 400 mg - sofosbuvir

ישראל - עברית - Ministry of Health

manon pharm ltd. - ascorbic acid; betacarotene; biotin; calcium carbonate; calcium pantothenate; chromium as chloride; colecalciferol; copper; cyanocobalamin; ferrous fumarate; folic acid; magnesium oxide; manganese as sulfate; nicotinamide; potassium iodide; pyridoxine (vit b6) hydrochloride; riboflavine; sodium molybdate; sodium selenate; thiamine (vit b1) mononitrate; tocopherol (vit e) (as tocopheryl acetate); vitamin a; zinc as oxide - טבליה - betacarotene 1500 iu; vitamin a 1500 iu; ascorbic acid 100 mg; folic acid 1 mg; riboflavine 3.4 mg; nicotinamide 20 mg; cyanocobalamin 12 mcg; colecalciferol 250 iu; biotin 30 mcg; copper 2 mg; sodium molybdate 25 mcg; manganese as sulfate 5 mg; zinc as oxide 25 mg; ferrous fumarate 60 mg; potassium iodide 0.15 mg; magnesium oxide 50 mg; chromium as chloride 25 mcg; calcium pantothenate 10 mg; pyridoxine (vit b6) hydrochloride 10 mg; thiamine (vit b1) mononitrate 3 mg; tocopherol (vit e) (as tocopheryl acetate) 30 iu; calcium carbonate 250 mg; sodium selenate 25 mcg - vitamin and mineral supplement for use during pregnancy and lactation.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 20 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

ישראל - עברית - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 30 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient.treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

ישראל - עברית - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.